High-Dose Interferon Alfa-2b Does Not Diminish Antibody Response to GM2 Vaccination in Patients With Resected Melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696
- 1 March 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (5) , 1430-1436
- https://doi.org/10.1200/jco.2001.19.5.1430
Abstract
PURPOSE: High-dose interferon alfa-2b (IFNα2b) is the only established adjuvant therapy of resectable high-risk melanoma. GM2-KLH/QS-21 (GMK) is a chemically defined vaccine that is one of the best...Keywords
This publication has 7 references indexed in Scilit:
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190Journal of Clinical Oncology, 2000
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.Journal of Clinical Oncology, 1994
- Cultured Human Melanocytes from Black and White Donors Have Different Sunlight and Ultraviolet A Radiation SensitivitiesJournal of Investigative Dermatology, 1992
- Studies of a ganglioside fraction extracted from human malignant melanomaBiochimie, 1976
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958